What is the clinical evidence from this study?

Study design: Review. Population: Cardiac arrhythmias. Intervention: Vaughan Williams classification of antiarrhythmic drugs.

What does this research mean for the field?

The Vaughan Williams classification of antiarrhythmic drugs remains a foundational and clinically useful framework that has been recently expanded to incorporate modern knowledge of arrhythmia mechanisms and novel drug targets. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the biographical background and experimental findings supporting Edward Miles Vaughan Williams' classification of antiarrhythmic drugs, its clinical shortcomings, and its modern expansion.

September 8, 2026Naunyn-Schmiedeberg s Archives of PharmacologyOpen Access

Edward Miles Vaughan Williams’ classification of antiarrhythmic drugs: then and now

View Full Paper

Ask AI

Bookmark

Key result

Modernized Vaughan Williams classification remains clinically useful by incorporating novel molecular targets and arrhythmia mechanisms.

Design

Historical review

Authors

ACAnthony CoteUniversity of Freiburg RPRémi PeyronnetUniversity of Freiburg URUrsula RavensElectrophysiology

Discussion

Member takes

Implication

Supports continued clinical use of the modernized Vaughan Williams framework; leaves open prospective validation of expanded targets.

Key Points

To review the biographical background and experimental findings supporting Edward Miles Vaughan Williams' classification of antiarrhythmic drugs, its clinical shortcomings, and its modern expansion.
Reviewed historical pharmacological experiments establishing the original three classes of antiarrhythmic drug actions (sodium channel block, sympathetic suppression, and action potential duration prolongation).
Analyzed clinical trial outcomes such as the Cardiac Arrhythmia Suppression Trial (CAST) and alternative systems including The Sicilian Gambit.
The initial three-part scheme expanded over time to subdivide class I actions and incorporate class IV calcium channel antagonism exemplified by verapamil.
The complex Sicilian Gambit classification failed to replace the original system in routine clinical cardiology practice due to excessive complexity.
Modern consensus frameworks retain the original intuitive structure while incorporating newly identified molecular targets and mechanisms underlying cardiac arrhythmias.

PICO

Population

Cardiac arrhythmias

Intervention / Comparator

Vaughan Williams classification of antiarrhythmic drugs

This historical review traces the evolution of the Vaughan Williams classification of antiarrhythmic drugs from its inception to its modern expansion, highlighting its enduring clinical utility.

Limitations

The original classification was historically criticized for being incomplete, not sufficiently systematic, and failing to predict proarrhythmic mortality risks as seen in the CAST trial.

Cite This Study

Cote et al. (2026) conducted a review in Cardiac arrhythmias. Vaughan Williams classification of antiarrhythmic drugs was evaluated. The Vaughan Williams classification of antiarrhythmic drugs remains a foundational and clinically useful framework that has been recently modernized to incorporate novel molecular targets and arrhythmia mechanisms.

synapsesocial.com/papers/6a9fd77658e84d0ff5b462cf https://doi.org/10.1007/s00210-026-05861-1

View Full Paper

Ask AI

Bookmark

Edward Miles Vaughan Williams’ classification of antiarrhythmic drugs: then and now

Discussion

Member takes

Implication

Key Points

PICO

Limitations

Cite This Study

Edward Miles Vaughan Williams’ classification of antiarrhythmic drugs: then and now

Discussion

Member takes

Implication

Key Points

PICO

Limitations

Cite This Study

Also Consider

Also Consider